Aviron Inc. (AVIR)

HEALTH CARE: PHARMACEUTICALS *** This stock is shown as delisted in our database. *** If you think this isn't correct then please let us know

Aviron is a biopharmaceutical company which focuses on prevention of disease through innovative vaccine technology. The vaccine development programs are based on techniques for producing attenuated live virus vaccines and proprietary genetic engineering technologies. The vaccines are for preventing diseases like smallpox, polio, measles, mumps, rubella and chicken pox. The company offers two types of vaccines namely Inactivated and subunit virus vaccines and Live virus vaccines. Inactivated virus vaccines are produced by killing a virus using chemicals or by making pieces of viruses using molecular or biochemical techniques. These vaccines offer the advantage of little or no risk of infection from the vaccine itself, assuming the virus has been adequately inactivated. Live virus vaccines expose the immune system to a weakened form of the virus that can trigger a lasting immune response to the wild-type virus without causing illness.

Are you looking for this stock instead?

View SEC Filings from AVIR instead.
Q1 2021 All 13F Filers Prior Change Hedge Funds 1 Prior Change
No data found for this quarter.
1 hedge funds and active managers as identified by whalewisdom.com through public filings.

View recent insider trading info

Funds Holding AVIR (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding AVIR BETA

Active Schedule 13D and 13G filings

Please sign in first

Open Market Buys/Sells Last 60 Days

Open Market Buys (P)

none

Open Market Sells (S)

none

Exercise Derivative Conversion (M)

none

Current/Former Insiders

Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

BERGER FRANKLIN M

  • Director
34,025 2021-06-18 4

DUNCAN BARBARA GAYLE

  • Director
34,025 2021-06-18 3

POLSKY BRUCE

  • Director
34,025 2021-06-18 3

MURPHY POLLY A.

  • Director
34,025 2021-06-18 3

LUCIDI BRUNO

  • Director
34,025 2021-06-18 3

ADAMS JEROME M.

  • Director
0 2021-05-18 2

CORCORAN ANDREA SEE REMARKS

  • Officer
0 2021-01-29 3

HORGA MARIA ARANTXA CHIEF MEDICAL OFFICER

  • Officer
0 2021-01-29 2

HAMMOND JANET MJ CHIEF DEVELOPMENT OFFICER

  • Officer
0 2021-01-29 2

FOSTER WAYNE SEE REMARKS

  • Officer
0 2021-01-29 3

VAVRICKA JOHN CHIEF COMMERCIAL OFFICER

  • Officer
0 2021-01-29 3

SOMMADOSSI JEAN-PIERRE PRESIDENT, CEO, AND CHAIRMAN

  • Officer
  • Director
0 2021-01-29 3

HACK ANDREW A. F.

  • Director
5,615,659 2020-11-03 3

CHU CHUNG K.

  • 10% Owner
No longer subject to file 2020-11-03 2

ROCK SPRINGS CAPITAL MANAGEMENT LP

ROCK SPRINGS CAPITAL MASTER FUND LP

ROCK SPRINGS CAPITAL LLC

  • 10% Owner
No longer subject to file 2020-11-03 2

CORMORANT ASSET MANAGEMENT, LP

CHEN BIHUA

CORMORANT PRIVATE HEALTHCARE FUND II, LP

CORMORANT GLOBAL HEALTHCARE MASTER FUND, LP

CORMORANT PRIVATE HEALTHCARE FUND I, LP

  • Director
  • 10% Owner
  • FORMER 10% OWNER
No longer subject to file 2020-11-03 1

CORMORANT ASSET MANAGEMENT, LP

CHEN BIHUA

CORMORANT PRIVATE HEALTHCARE FUND I, LP

CORMORANT PRIVATE HEALTHCARE FUND II, LP

  • Director
  • 10% Owner
0 2020-10-29 1

SOMMADOSSI JEAN-PIERRE PRESIDENT, CEO, AND CHAIRMAN

JPM PARTNERS LLC

  • Officer
  • Director
  • 10% Owner
5,175,000 2020-10-29 3

CHENG ISAAC

  • Director
0 2020-10-29 2

Insider Transactions Last 60 Days

Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
Disposed
Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days

MURPHY POLLY A. - Director

2021-06-21 17:30:10 -0400 2021-06-18 A 34,025 a 34,025 direct

LUCIDI BRUNO - Director

2021-06-21 17:36:06 -0400 2021-06-18 A 34,025 a 34,025 direct

BERGER FRANKLIN M - Director

2021-06-21 17:34:55 -0400 2021-06-18 A 34,025 a 34,025 direct

POLSKY BRUCE - Director

2021-06-21 17:36:56 -0400 2021-06-18 A 34,025 a 34,025 direct

DUNCAN BARBARA GAYLE - Director

2021-06-21 17:35:15 -0400 2021-06-18 A 34,025 a 34,025 direct

* -

Transaction Code Definitions
Code Definition
A Grant, award or other acquisition pursuant to Rule 16b-3(d)
C Conversion of derivative security
D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
E Expiration of short derivative position
F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
G Bona fide gift
H Expiration (or cancellation) of long derivative position with value received
I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
J Other acquisition or disposition
L Small acquisition under Rule 16a-6
M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
O Exercise of out-of-the-money derivative security
P Open market or private purchase of non-derivative or derivative security
S Open market or private sale of non-derivative or derivative security
U Disposition pursuant to a tender of shares in a change of control transaction
W Acquisition or disposition by will or the laws of descent and distribution
X Exercise of in-the-money or at-the-money derivative security
Z Deposit into or withdrawal from voting trust

IBR Securities Loan Availability

Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers

Security Date/Time Rebate Rate Fee Rate Shares Available

Current Active Short Positions

Holder Issuer Net Short Position Position Date Origin

Elevate your investments